0.0001
0.0000
(0.00%)
At close: January 10 at 3:00:00 PM EST
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
19,637.0000
19,637.0000
22,200.0000
--
Operating Expense
35,314.0000
35,314.0000
78,807.0000
79,701.0000
Operating Income
-15,677.0000
-15,677.0000
-56,607.0000
-79,701.0000
Net Non Operating Interest Income Expense
-9,228.0000
-9,228.0000
-3,426.0000
-2,704.0000
Other Income Expense
-4,963.0000
-4,963.0000
-495.0000
-527.0000
Pretax Income
-29,868.0000
-29,868.0000
-52,766.0000
-82,932.0000
Tax Provision
11.0000
11.0000
213.0000
34.0000
Net Income Common Stockholders
-29,879.0000
-29,879.0000
-52,979.0000
-82,966.0000
Diluted NI Available to Com Stockholders
-29,879.0000
-29,879.0000
-52,979.0000
-82,966.0000
Basic EPS
-0.32
--
-0.70
-1.67
Diluted EPS
-0.32
--
-0.70
-1.67
Basic Average Shares
92,080.9980
--
75,281.8380
49,820.4510
Diluted Average Shares
107,706.6990
--
75,281.8380
49,820.4510
Total Operating Income as Reported
-15,677.0000
-15,677.0000
-56,607.0000
-79,701.0000
Total Expenses
35,314.0000
35,314.0000
78,807.0000
79,701.0000
Net Income from Continuing & Discontinued Operation
-29,879.0000
-29,879.0000
-52,979.0000
-82,966.0000
Normalized Income
-24,439.3250
-24,439.3250
-59,081.0711
-82,439.0000
Interest Income
--
--
600.0000
648.0000
Interest Expense
9,228.0000
9,228.0000
3,426.0000
2,704.0000
Net Interest Income
-9,228.0000
-9,228.0000
-3,426.0000
-2,704.0000
EBIT
-20,640.0000
-20,640.0000
-49,340.0000
-80,228.0000
EBITDA
-20,073.0000
-20,073.0000
-48,677.0000
-79,507.0000
Reconciled Depreciation
567.0000
567.0000
663.0000
721.0000
Net Income from Continuing Operation Net Minority Interest
-29,879.0000
-29,879.0000
-52,979.0000
-82,966.0000
Total Unusual Items Excluding Goodwill
-5,945.0000
-5,945.0000
7,173.0000
-527.0000
Total Unusual Items
-5,945.0000
-5,945.0000
7,173.0000
-527.0000
Normalized EBITDA
-14,128.0000
-14,128.0000
-55,850.0000
-78,980.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
--
Tax Effect of Unusual Items
-505.3250
-505.3250
1,070.9289
--
12/31/2020 - 6/9/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IDIA.SW Idorsia Ltd
0.7790
-1.77%
SANN.SW Santhera Pharmaceuticals Holding AG
13.68
-2.84%
EVGN Evogene Ltd.
1.5700
-4.27%
KALA KALA BIO, Inc.
6.81
-0.15%
IMVT Immunovant, Inc.
23.48
-0.63%
CGON CG Oncology, Inc.
30.20
-0.85%
ADAP Adaptimmune Therapeutics plc
0.6200
+0.02%
CLLS Cellectis S.A.
1.8500
-4.15%
ARQT Arcutis Biotherapeutics, Inc.
13.81
-9.56%
APLS Apellis Pharmaceuticals, Inc.
27.44
-16.85%